Chemotherapy of MMR-deficient colorectal cancer

被引：44
作者：
Devaud, N. [1 ]
Gallinger, S. [1 ,2 ,3 ]
机构：
[1] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada
[2] Toronto Gen Hosp, UHN, Toronto, ON, Canada
[3] Univ Toronto, Hepatobiliary Pancreat Surg Oncol Program, Toronto Gen Hosp, Toronto, ON M5G 2C4, Canada
来源：
FAMILIAL CANCER | 2013年 / 12卷 / 02期
关键词：
Colorectal cancer; Microsatellite Instability; Chemotherapy; SURGICAL ADJUVANT BREAST; TUMOR MICROSATELLITE-INSTABILITY; SPORADIC COLON-CANCER; DNA MISMATCH REPAIR; STAGE-II; FLUOROURACIL; LEUCOVORIN; MUTATIONS; 5-FLUOROURACIL; OXALIPLATIN;
D O I：
10.1007/s10689-013-9633-z
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Colorectal cancer (CRC) continues to rank as the third most common cancer in Western society and the second leading cause of cancer death in North America. There are at least three distinct, and relatively discreet, molecular pathways associated with this disease: chromosomal instability (CIN), microsatellite instability (MSI) and the cytosine polyguanine island methylator phenotype. Defects in the DNA mismatch repair system (MMR) account for the MSI phenotype and genotype of about 15 % of CRC. Although high frequency MSI tumors have better stage independent prognosis compared to those with CIN, MMR deficient CRC appears to be resistant to fluorouracil based treatment, but sensitive to other therapeutic regimens. This review summarises current literature on differential chemosensitivity of MMR-deficient CRC.
引用
收藏
页码：301 / 306
页数：6
相关论文
共 39 条
[1]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]   Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].
Andre, Thierry ;
Boni, Corrado ;
Navarro, Matilde ;
Tabernero, Josep ;
Hickish, Tamas ;
Topham, Clare ;
Bonetti, Andrea ;
Clingan, Philip ;
Bridgewater, John ;
Rivera, Fernando ;
de Gramont, Aimery .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116
[3]   Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines [J].
Arnold, CN ;
Goel, A ;
Boland, CR .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (01) :66-73
[4]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[5]  
Boland CR, 1998, CANCER RES, V58, P5248
[6]  
Des Guetz G, 2007, ANTICANCER RES, V27, P2715
[7]   Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer [J].
Elsaleh, H ;
Joseph, D ;
Grieu, F ;
Zeps, N ;
Spry, N ;
Iacopetta, B .
LANCET, 2000, 355 (9217) :1745-1750
[8]   THE HUMAN MUTATOR GENE HOMOLOG MSH2 AND ITS ASSOCIATION WITH HEREDITARY NONPOLYPOSIS COLON-CANCER [J].
FISHEL, R ;
LESCOE, MK ;
RAO, MRS ;
COPELAND, NG ;
JENKINS, NA ;
GARBER, J ;
KANE, M ;
KOLODNER, R .
CELL, 1993, 75 (05) :1027-1038
[9]   Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer [J].
Gryfe, R ;
Kim, H ;
Hsieh, ETK ;
Aronson, MD ;
Holowaty, EJ ;
Bull, SB ;
Redston, M ;
Gallinger, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (02) :69-77
[10]   Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy [J].
Hemminki, A ;
Mecklin, JP ;
Järvinen, H ;
Aaltonen, LA ;
Joensuu, H .
GASTROENTEROLOGY, 2000, 119 (04) :921-928
1234